109 related articles for article (PubMed ID: 21858801)
1. Assessing the impact of comorbid illnesses on death within 10 years in prostate cancer treatment candidates.
Groome PA; Rohland SL; Siemens DR; Brundage MD; Heaton J; Mackillop WJ
Cancer; 2011 Sep; 117(17):3943-52. PubMed ID: 21858801
[TBL] [Abstract][Full Text] [Related]
2. Predictive validity of five comorbidity indices in prostate carcinoma patients treated with curative intent.
Boulos DL; Groome PA; Brundage MD; Siemens DR; Mackillop WJ; Heaton JP; Schulze KM; Rohland SL
Cancer; 2006 Apr; 106(8):1804-14. PubMed ID: 16534794
[TBL] [Abstract][Full Text] [Related]
3. Effects of long-term exposure to traffic-related air pollution on respiratory and cardiovascular mortality in the Netherlands: the NLCS-AIR study.
Brunekreef B; Beelen R; Hoek G; Schouten L; Bausch-Goldbohm S; Fischer P; Armstrong B; Hughes E; Jerrett M; van den Brandt P
Res Rep Health Eff Inst; 2009 Mar; (139):5-71; discussion 73-89. PubMed ID: 19554969
[TBL] [Abstract][Full Text] [Related]
4. Competing risk analysis after radical prostatectomy for clinically nonmetastatic prostate adenocarcinoma according to clinical Gleason score and patient age.
Sweat SD; Bergstralh EJ; Slezak J; Blute ML; Zincke H
J Urol; 2002 Aug; 168(2):525-9. PubMed ID: 12131302
[TBL] [Abstract][Full Text] [Related]
5. Is there an optimal comorbidity index for prostate cancer?
Alibhai SM; Leach M; Tomlinson GA; Krahn MD; Fleshner NE; Naglie G
Cancer; 2008 Mar; 112(5):1043-50. PubMed ID: 18286512
[TBL] [Abstract][Full Text] [Related]
6. Short- and long-term mortality with localized prostate cancer.
Merglen A; Schmidlin F; Fioretta G; Verkooijen HM; Rapiti E; Zanetti R; Miralbell R; Bouchardy C
Arch Intern Med; 2007 Oct; 167(18):1944-50. PubMed ID: 17923593
[TBL] [Abstract][Full Text] [Related]
7. Impact of comorbidity on treatment and prognosis of prostate cancer patients: a population-based study.
Houterman S; Janssen-Heijnen ML; Hendrikx AJ; van den Berg HA; Coebergh JW
Crit Rev Oncol Hematol; 2006 Apr; 58(1):60-7. PubMed ID: 16213153
[TBL] [Abstract][Full Text] [Related]
8. The incidence and impact of comorbidity diagnosed after the onset of head and neck cancer.
Yung KC; Piccirillo JF
Arch Otolaryngol Head Neck Surg; 2008 Oct; 134(10):1045-9. PubMed ID: 18936348
[TBL] [Abstract][Full Text] [Related]
9. Greater influence of age than co-morbidity on primary treatment and complications of prostate cancer patients: an in-depth population-based study.
Houterman S; Janssen-Heijnen ML; Verheij CD; Kil PJ; van den Berg HA; Coebergh JW
Prostate Cancer Prostatic Dis; 2006; 9(2):179-84. PubMed ID: 16534509
[TBL] [Abstract][Full Text] [Related]
10. The Charlson comorbidity score: a superior comorbidity assessment tool for the prostate cancer multidisciplinary meeting.
Kastner C; Armitage J; Kimble A; Rawal J; Carter PG; Venn S
Prostate Cancer Prostatic Dis; 2006; 9(3):270-4. PubMed ID: 16770340
[TBL] [Abstract][Full Text] [Related]
11. 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort.
Albertsen PC; Hanley JA; Penson DF; Barrows G; Fine J
J Urol; 2007 Mar; 177(3):932-6. PubMed ID: 17296379
[TBL] [Abstract][Full Text] [Related]
12. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
13. Impact of comorbidity on survival of Danish prostate cancer patients, 1995-2006: a population-based cohort study.
Lund L; Borre M; Jacobsen J; Sørensen HT; Nørgaard M
Urology; 2008 Dec; 72(6):1258-62. PubMed ID: 18342917
[TBL] [Abstract][Full Text] [Related]
14. Major 30-day complications after radical radiotherapy: a population-based analysis and comparison with surgery.
Alibhai SM; Leach M; Warde P
Cancer; 2009 Jan; 115(2):293-302. PubMed ID: 19025976
[TBL] [Abstract][Full Text] [Related]
15. Comorbidity measurement in patients with laryngeal squamous cell carcinoma.
Castro MA; Dedivitis RA; Ribeiro KC
ORL J Otorhinolaryngol Relat Spec; 2007; 69(3):146-52. PubMed ID: 17264530
[TBL] [Abstract][Full Text] [Related]
16. "Just Another Statistic".
Machtay M; Glatstein E
Oncologist; 1998; 3(3):III-IV. PubMed ID: 10388105
[TBL] [Abstract][Full Text] [Related]
17. Predictors of mortality after androgen-deprivation therapy in patients with rapidly rising prostate-specific antigen levels after local therapy for prostate cancer.
Rodrigues NA; Chen MH; Catalona WJ; Roehl KA; Richie JP; D'Amico AV
Cancer; 2006 Aug; 107(3):514-20. PubMed ID: 16795068
[TBL] [Abstract][Full Text] [Related]
18. The 20-Yr outcome in patients with well- or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and comorbidity.
Adolfsson J; Tribukait B; Levitt S
Eur Urol; 2007 Oct; 52(4):1028-35. PubMed ID: 17467883
[TBL] [Abstract][Full Text] [Related]
19. Comorbid survival among elderly male participants of the Canada health survey: relevance to prostate cancer screening and treatment.
Eapen L; Villeneuve PJ; Levy IG; Morrison HI
Chronic Dis Can; 1998; 19(3):84-90. PubMed ID: 9820831
[TBL] [Abstract][Full Text] [Related]
20. Charlson comorbidity index as a predictor of long-term outcome after surgery for nonsmall cell lung cancer.
Birim O; Kappetein AP; Bogers AJ
Eur J Cardiothorac Surg; 2005 Nov; 28(5):759-62. PubMed ID: 16157485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
